Molecular classification of colorectal cancer: A dream that can become a reality

Romanian Journal of Morphology and Embryology

Volumn 54, Issue 2, 2013, Pages 241-245

  Gurzu, Simona ^a   Szentirmay, Z ^b   Jung, I ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Colorectal cancer; Maspin; Microsatellite instability; Molecular classification; Prognostic; Therapy

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; SERINE PROTEINASE INHIBITOR; SERPIN B5; SERPIN-B5;

CLASSIFICATION; COLORECTAL TUMOR; GENETICS; HUMAN; METHODOLOGY; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSIS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REVIEW;

COLORECTAL NEOPLASMS; HUMANS; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSTIC TECHNIQUES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SERPINS;

EID: 84879178736     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Jemal A, Siegel R, Xu J, Ward E, Cancer statistics, 2010, CA Cancer J Clin, 2010, 60(5):277-300.
2. Vasile L, Olaru A, Munteanu M, Pleşea IE, Surlin V, Tudoraşcu C, Prognosis of colorectal cancer: clinical, pathological and therapeutic correlation, Rom J Morphol Embryol, 2012, 53(2):383-391.
3. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Rüschoff J, Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression, Cancer Res, 1997, 57(21):4749-4756.
4. Gurzu S, Szentirmay Z, Popa D, Jung I, Practical value of the new system for Maspin assessment, in colorectal cancer, Neoplasma, 2013 Apr 15.
5. Turaga K, Shibata D, K-Ras and MSI: potential markers of both patient prognosis and treatment efficacy, Ann Surg Oncol, 2010, 17(2):354-355.
6. Janavicius R, Matiukaite D, Jakubauskas A, Griskevicius L, Microsatellite instability detection by high-resolution melting analysis, Clin Chem, 2010, 56(11):1750-1757.
7. Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, Rutegård J, Palmqvist R, Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor, Mod Pathol, 2011, 24(5):671-682.
8. Shima K, Morikawa T, Yamauchi M, Kuchiba A, Imamura Y, Liao X, Meyerhardt JA, Fuchs CS, Ogino S, TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers, PLoS One, 2011, 6(9):e25062.
9. Tóth E, Serester O, Gallai M, Gurzu S, Jung I, Szentirmay Z, Molecular pathways and pathomorphology of colorectal cancers, Rom J Morphol Embryol, 2011, 52(3):767-773.
10. Gurzu S, Jung I, Aberrant pattern of the cytokeratin 7/ cytokeratin 20 immunophenotype in colorectal adeno-carcinomas with BRAF mutations, Pathol Res Pract, 2012, 208(3):163-166.
11. Bayrak R, Yenidünya S, Haltas H, Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas, Pathol Res Pract, 2011, 207(3):156-160.
12. Chênevert J, Bessette P, Plante M, Têtu B, Dubé V, Mixed ovarian large cell neuroendocrine carcinoma, mucinous adenocarcinoma, and teratoma: a report of two cases and review of the literature, Pathol Res Pract, 2009, 205(9):657-661.
13. Gurzu S, Szentirmay Z, Toth E, Jung I, Possible predictive value of Maspin expression in colorectal cancer, Recent Pat Anticancer Drug Discov, 2013, 8(2):183-190.
14. Ravenhill L, Wagstaff L, Edwards DR, Ellis V, Bass R, G-helix of Maspin mediates effects on cell migration and adhesions, J Biol Chem, 2010, 285(47):36285-36292.
15. Märkl B, Arnholdt HM, Jähnig H, Schenkirsch G, Herrmann RA, Haude K, Spatz H, Anthuber M, Schlimok G, Oruzio D, Shift from cytoplasmic to nuclear Maspin expression correlates with shorter overall survival in node-negative colorectal cancer, Hum Pathol, 2010, 41(7):1024-1033.
16. Dietmaier W, Bettstetter M, Wild PJ, Woenckhaus M, Rümmele P, Hartmann A, Dechant S, Blaszyk H, Pauer A, Klinkhammer-Schalke M, Hofstädter F, Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer, Int J Cancer, 2006, 118(9):2247-2254.
17. O'Brien MJ, Yang S, Mack C, Xu H, Huang CS, Mulcahy E, Amorosino M, Farraye FA, Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points, Am J Surg Pathol, 2006, 30(12):1491-1501.
18. Stefanius K, Ylitalo L, Tuomisto A, Kuivila R, Kantola T, Sirniö P, Karttunen TJ, Mäkinen MJ, Frequent mutations of KRAS in addition to BRAF in colorectal serrated adeno-carcinoma, Histopathology, 2011, 58(5):679-692.
19. Gurzu S, Szentirmay Z, Toth E, Bara T, Bara T Jr, Jung I, Serrated pathway adenocarcinomas: molecular and immuno-histochemical insights into their recognition, PLoS One, 2013, 8(3):e57699.
20. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P, KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial, J Clin Oncol, 2009, 27(35):5931-5937.
21. Neumann J, Reu S, Kirchner T, Prognostic marker profiles for risk of distant metastases in colorectal cancer, Pathologe, 2012, 33(1):39-44.
22. Cartwright TH, Treatment decisions after diagnosis of metastatic colorectal cancer, Clin Colorectal Cancer, 2012, 11(3):155-166.
23. Aloysius MM, Zaitoun AM, Beckingham IJ, Neal KR, Aithal GP, Bessell EM, Lobo DN, The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study, Virchows Arch, 2007, 451(5):943-948.
24. Butt W, Saadati H, Saif MW, Oxaliplatin-induced pancreatitis: a case series, Anticancer Res, 2010, 30(12):5113-5116.
25. Jensen NF, Smith DH, Nygård SB, Rømer MU, Nielsen KV, Brünner N, Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer, Scand J Gastroenterol, 2012, 47(3):340-355.
26. Hong SP, Min BS, Kim TI, Cheon JH, Kim NK, Kim H, Kim WH, The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer, Eur J Cancer, 2012, 48(8): 1235-1243.
27. Weber T, Link KH, Multimodal therapy for colon cancer: state of the art, Zentralbl Chir, 2011, 136(4):325-333.
28. Dotan E, Cohen SJ, Challenges in the management of stage II colon cancer, Semin Oncol, 2011, 38(4):511-520.
29. Catwright TH, Yim YM, Yu E, Chung H, Halm M, Forsyth M, Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US Community Oncology, Clin Colorectal Cancer, 2012, 11(4):238-246.
30. Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F, Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer, Expert Opin Investig Drugs, 2012, 21(7):949-959.
31. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, wagner A, Laurent D; CORRECT Study Group, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, 2013, 381(9863):303-312.
32. Qin L, Zhang M, Maspin regulates endothelial cell adhesion and migration through an integrin signaling pathway, J Biol Chem, 2010, 285(42):32360-32369.
33. Li Z, Shi HY, Zhang M, Targeted expression of Maspin in tumor vasculatures induces endothelial cell apoptosis, Oncogene, 2005, 24(12):2008-2019.
34. Sonoda H, Mekata E, Shimizu T, Endo Y, Tani T, Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution, Oncol Lett, 2013, 5(4):1331-1334.
35. Ghiţǎ C, Vîlcea ID, Dumitrescu M, Vîlcea AM, Mirea CS, Aşchie M, Vasilescu F, The prognostic value of the immunohistochemical aspects of tumor suppressor genes p53, bcl-2, PTEN and nuclear proliferative antigen Ki-67 in resected colorectal carcinoma, Rom J Morphol Embryol, 2012, 53(3):549-556.
36. Oliveras-Ferraros C, Massaguer Vall-Llovera A, Vazquez-Martin A, Salip DC, Queralt B, Cufí S, Martin-Castillo B, Bosch-Barrera J, Brunet J, De Llorens R, Menendez JA, Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment, Oncol Rep, 2012, 27(6):1887-1892.
37. Nakamoto K, Nagahara H, Maeda K, Noda E, Inoue T, Yashiro M, Nishiguchi Y, Ohira M, Hirakawa K, Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer, Oncol Lett, 2013, 5(4):1295-1300.